Chargement en cours...
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete respon...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
National Academy of Sciences
2004
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC423259/ https://ncbi.nlm.nih.gov/pubmed/15161974 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0402653101 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|